UR-3216: a new generation oral platelet GPIIb/IIIa antagonist.


Various oral platelet GPIIb/IIIa receptor antagonists have undergone clinical investigations, but to date without success. Various factors have been proposed to explain their failure such as low affinity for the receptor, large peak/trough ratio, low bioavailability, partial agonist activity and pro-aggregatory effect. Efforts to discover a truly effective… (More)


  • Presentations referencing similar topics